Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For mo
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... RALEIGH, N.C. and ,S-HERTOGENBOSCH, the ... Europe ( http://www.healthlinkeurope.com ) has expanded its North American ... 100% medical facility, providing warehousing, fulfillment and order to ... North America , utilizing our global ERP platform. ... since 1994 serving our customers in Europe ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
(Date:9/2/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes Novian Health, Inc. with the ... Technology Innovation Leadership. Novian Health has greatly improved ... with its proprietary technology, Novilase ® Laser ... and easy-to-control ultrasound-guided thermo ablation device that performs ...
Breaking Medicine Technology:HealthLink Europe opens North American medical warehouse operation 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... 15 GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an ... and provided an,operational update for the quarter ended September ... September 30, 2007 The Company recorded a net ... 2007, compared to $283,434 for the same period in ...
... BRISBANE, Calif., Nov. 15 BiPar,Sciences, Inc., a ... announced it has initiated a Phase 2 study ... triple-negative breast,cancer that do not express the estrogen, ... the Phase 2 trial in this indication-which,represents a ...
Cached Medicine Technology:GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 6GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 7GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 8GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 9GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 10BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
(Date:9/2/2014)... with less intensive (and expensive) practice patterns appear to ... patients unnecessary and excessive medical care, according to a ... "Growing concern about the costs and harms of medical ... avoid the provision of unnecessary care," said lead author ... Dartmouth Institute for Health Policy & Clinical Practice. ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Evolve ... within the primary and urgent care arena, is ... opening coincides with a health fair the clinic ... incorporating technology to assist patients in achieving high ... Medical Clinics’ pricing structure is a groundbreaking change ...
(Date:9/2/2014)... 2014 The first trial involving ... implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon get underway, ... District Court, Northern District of Texas, Bernstein Liebhard ... Johnson and its DePuy Orthopaedics unit are facing ... caused recipients to suffer serious and debilitating complications. ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... California, San Diego School of Medicine have identified an ... The findings, reported in the current issue of PNAS, ... mortality worldwide. An estimated 40,000 women in America will ... American Cancer Society. , "The take-home message of the ... target breast cancer metastasis through a pathway regulated by ...
Breaking Medicine News(10 mins):Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Enzyme controlling metastasis of breast cancer identified 2
... But researcher stresses risk is still low , , MONDAY, Jan. ... the risk of developing brain cancer at a young age ... people with malignant brain tumors and 238 people with no ... most common type of brain cancer. Patients survive an average ...
... heart disease to rest , , MONDAY, Jan. 26 (HealthDay News) ... in vegetable oils, nuts and seeds possibly being bad for ... American Heart Association claims. , "There has been a lot ... might be bad," said William S. Harris, the nutritionist heading ...
... of American Physicians, Inc. Chief Executive Officer James L. ... Spirit of Life(R) Award, City of Hope,s ... celebrating Mr. Weidner and his award will be held ... Saturday, November 14. Spirit of Life(R) Award honorees ...
... Buy is Exclusive Retail Partner WARREN, N.J., Jan. ... VM ) announced today that it is joining ... of the LG Pink Flare limited edition handset, ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090126/NY62794 ) , (Logo: ...
... Nephros, Inc. (Pink Sheets: NEPH), a medical device company ... control, and water purification, today announced that its common ... the symbol "NEPH." The Company also announced that ... the NYSE Alternext US LLC (formerly, the American Stock ...
... people tend to overestimate the dangers, study finds, , , ... the minds of U.S. minorities and the disabled more ... , Ethnic minorities, as well as the disabled and ... changes based on terrorism fears, such as avoiding certain ...
Cached Medicine News:Health News:Omega-6 Fatty Acids Can Be Good for You 2Health News:Omega-6 Fatty Acids Can Be Good for You 3Health News:James L. Weidner Named 2009 Spirit of Life(R) Award Recipient by City of Hope 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 3Health News:Nephros Common Stock Now Quoted in Pink Sheets 2Health News:Nephros Common Stock Now Quoted in Pink Sheets 3Health News:Terror Fears Tougher on Minorities, Disabled 2Health News:Terror Fears Tougher on Minorities, Disabled 3
... 400 System is an automated multiplexing platform ... SNP detection, pathogen sequence detection and pharmacogenetics ... be applied to an open and flexible ... be reused until all tests sites have ...
... venous pressure monitoring, blood sampling, and ... polyurethane PICC line sets offer:, , ... Micropuncture Introducer Needle, Biocompatible Polyurethane ... to patient specific anatomy. Remove catheter ...
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Medicine Products: